Intellect Neurosciences Inc (ILNS)

Description:

Intellect Neurosciences Inc was incorporated in Delaware on April 25, 2005 under the name Eidetic Biosciences, Inc. and changed its name to Mindset Neurosciences, Inc. on April 28, 2005, to Lucid Neurosciences, Inc. on May 17, 2005 and to Intellect Neurosciences, Inc. on May 20, 2005. On January 25, 2007, the Company completed the merger and Intellect became its wholly-owned subsidiary and changed its name to Intellect USA, Inc. Following the merger, its sole business is the business operated by Intellect. The Company discovers and develops therapeutic agents for the treatment and prevention of proteinopathies, which include Alzheimers, Parkinsons, and Huntington diseases. The Company's preclinical research and development pipeline is based on proprietary platform technologies, such as ANTISENILIN, CONJUMAB, OLIGOTOPE, and RECALL-VAX. Its product candidates include OX1, an orally-administered, brain-penetrating, and naturally-occurring copper-binding small molecule, which has completed Phase-I clinical trial for the treatment of Friedreich's Ataxia, and Parkinsons and Wilsons diseases. The Company's preclinical products comprise CONJUMAB-A, an antibody drug conjugate for treatment of proteinopathies; and TOC-1 and RV03 for the treatment of Alzheimers disease, as well as other tauopathies, such as Frontotemporal dementia. It is also developing IN-N01, a preclinical IgG4 therapeutic antibody that promotes the clearance of monomeric, oligomeric, and plaque forms of amyloid beta, which accumulate in the brains of Alzheimer's patients or following traumatic brain injury; and in the retina of the eye in patients with age-related macular degeneration, diabetic neuropathy, and glaucoma. The Company has license agreements with University of South Alabama Medical Science Foundation, New York University, Northwestern University, AHP Manufacturing BV, Glaxo Group Limited, and ViroPharma; and collaboration agreement with MRC Technology.